Monitoring chronic hemodialysis patients: A questionnaire-based survey

International Journal of Artificial Organs

Volumn 31, Issue 8, 2008, Pages 730-736

  Presta, Pierangela ^a   Fuiano, L ^a   Comi, N ^a   Andreucci, M ^a   Gigliotti, P ^a   Tozzo, C ^b   Fuiano, G ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Hemodialysis; Monitoring program; Questionnaire

Indexed keywords

HEMODIALYZERS; PATIENT MONITORING; PATIENT TREATMENT; SURVEYS;

'CURRENT; FOLLOW UP; HAEMODIALYSIS; HEMODIALYSIS PATIENT; MONITORING PROGRAMMES; QUESTIONNAIRE; RESPONSE DATA; ROUTINE TESTS;

DIALYSIS;

ALUMINUM; CALCIUM PHOSPHATE; DIALYSIS FLUID;

ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FOLLOW UP; HEALTH PROGRAM; HEALTH SURVEY; HEMODIALYSIS PATIENT; HUMAN; ITALY; MAJOR CLINICAL STUDY; NEPHROLOGIST; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; QUESTIONNAIRE;

EID: 55249086931     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880803100807     Document Type: Article

References (39)

1. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23: 661-9.
2. Gotch FA, Levin NW, Port FK, Wolfe RA, Uehlinger DE. Clinical outcome relative to the dose of dialysis is not what you think: the fallacy of the mean. Am J Kidney Dis 1997; 30: 1-15.
3. Owen WF, Chertow GM, Lazarus JM, Lowrie EG. Dose of hemodialysis and survival: differences by race and sex. JAMA 1998; 280: 1764-68.
4. Section II. Hemodialysis adequacy. Nephrol Dial Transplant 2002; 17 (Suppl 7): S16-31.
5. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006; 48 (Suppl 1): S2-90.
6. Clinical practice guidelines for vascular access. Am J Kidney Dis 2006; 48 (Suppl 1): S176-247.
7. Clinical practice guidelines for vascular access. Am J Kidney Dis 2006; 48 (Suppl 1): S248-73.
8. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-82.
9. Clinical practice guidelines for nutrition in chronic renal failure. DOQI, National Kidney Foundation. Am J Kidney Dis 2000; 35 (6 Suppl. 2): S1-140. Erratum in: Am J Kidney Dis 2001; 38: 917.
10. Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 2004; 43: 558-65.
11. Salusky IB, Goodman WG. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 2002; 17: 336-9.
12. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45: S1-153.
13. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-201.
14. Coen G, Batlanti P, Bonucci E, et al. Bone markers in the diagnosis of low turnover osteodystrophy in hemodialysis patients. Nephrol Dial Transplant 1998; 13: 2294-302.
15. Couttenye MM, D'Haese PC, Van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in hemodialysis patients. Nephrol Dial Transplant 1996; 11: 1065-72.
16. Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 506-12.
17. Slatopolsky E. The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Kidney Int 1987; 31: 842-54.
18. Kausz AT, Antonsen JE, Hercz G, et al. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kidney Dis 199; 34: 688-93.
19. Johnson DW, McIntyre HD, Brown A, Freeman J, Rigby RJ. The role of DEXA bone densitometry in evaluating renal osteodystrophy in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1996; 16: 34-40.
20. K/DOQI Clinical Practice Guidelines for managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis 2003; 41 (Suppl 3): S1-92.
21. Davison AM. European Best Practice Guidelines for Hemodialysis (Part 1). Section VII (Vascular disease and risk factors) Microinflammatory state. Nephrol Dial Transplant 2002; 17 (Suppl 7): S100-9.
22. Covic A, Goldsmith DJ, Georgescu G, Venning MC, Ackrill R Echocardiographic findings in long-term, long-hour hemodialysis patients. Clin Nephrol 1996; 45: 104-10.
23. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996; 49: 1428-34.
24. Evans RW, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. JAMA 1990; 263: 825-30.
25. Locatelli F, Aljama P, Barany P, et. al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 (Suppl 2): ii1-47.
26. European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant 1999; 14 (Suppl 5): S1-37.
27. National Kidney Foundation. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 2006; 47 (Suppl 3): S16-85.
28. Locatelli F, Fouque D, Heimburger O, et al. Nutritional status in dialysis patients: a European consensus. Nephrol Dial Transplant 2002; 17: 563-72.
29. Pifer TB, McCullough KP, Port FK, et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002; 62: 2238-45.
30. European Best Practice Guidelines for Haemodialysis (Part 1). Section VI. Hemodialysis-associated infection. Nephrol Dial Transplant 2002; 17 (Suppl 7): S72-87.
31. Grantham JJ. Acquired cystic kidney disease. Kidney Int 1991; 40: 143-52.
32. Levine E, Slusher SL, Grantham JJ, Wetzel LH. Natural history of acquired renal cystic disease in dialysis patients: a prospective longitudinal CT study. AJR Am J Roentgenol 1991; 156: 501-6.
33. Marple JT, MacDougall M, Chonko AM. Renal cancer complicating acquired cystic kidney disease. J Am Soc Nephrol 1994; 4: 1951-6.
34. Dember LM, Jaber BL. Dialysis-related amyloidosis: late finding or hidden epidemic? Semin Dial 2006; 19: 105-9.
35. Higuchi N, Maruyama H. Diagnosis and therapy for beta2-microglobulin amyloidosis in the K/DOQI guideline. Clin Calcium 2004; 14: 744-9.
36. Perneger TV, Brancati FL, Whelton PK, Klag MJ. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med 1994; 121: 912-8.
37. Wolfe RA, Gaylin DS, Port FK, Held PJ, Wood CL. Using USRDS generated mortality tables to compare local ESRD mortality rates to national rates. Kidney Int 1992; 42: 991-6.
38. Dikow R, Ritz E. Cardiovascular complications in the diabetic patient with renal disease: an update in 2003. Nephrol Dial Transplant 2003; 18: 1993-8.
39. European Best Practice Guidelines for Haemodialysis (Part 1). Section IV. Dialysis fluid purity. Nephrol Dial Transplant 2002; 17 (Suppl 7): S45-62.